[Pubmed] Triple M Syndrome Associated With Concurrent Durvalumab and Olaparib Therapy in Metastatic Cholangiocarcinoma:
Posté : 24 juin 2026 12:00
Case Rep Oncol Med. 2026 Jun 22;2026:1318038. doi: 10.1155/crom/1318038. eCollection 2026.
ABSTRACT
Triple M syndrome is a rare and life-threatening overlap presentation of myocarditis, myositis and myasthenia gravis, secondary to immune checkpoint inhibition. We report a case of an 80-year-old female with metastatic cholangiocarcinoma, presenting with progressive asthenia, ptosis and dysphagia, following completion of six cycles of combination chemotherapy and immunotherapy, durvalumab. Her symptoms emerged 2 weeks after the commencement of maintenance therapy with immune checkpoint inhibitor, durvalumab, and poly(ADP-ribose) polymerase inhibitor, olaparib. Biochemical investigations were suspicious for myocarditis, myositis and type 2 respiratory failure due to myasthenic crisis. Clinical findings supported the diagnosis of triple M syndrome, and she was treated with high-dose steroids, intravenous immunoglobulin and supported with non-invasive ventilation. The patient initially improved; however, her admission was complicated by a fatal retroperitoneal haemorrhage. Our case highlights the need to consider serious immune-related adverse events and escalate prompt management for overlap syndromes in the context of immunotherapy and poly(ADP-ribose) polymerase inhibitors.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT06441747.
PMID:42338513 | PMC:PMC13284893 | DOI:10.1155/crom/1318038
Source: https://pubmed.ncbi.nlm.nih.gov/4233851 ... 9&v=2.20.0